search
Back to results

Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial (CATCO)

Primary Purpose

COVID-19

Status
Active
Phase
Phase 3
Locations
Canada
Study Type
Interventional
Intervention
Artesunate
Imatinib
Infliximab
Dexamethasone
LSALT Peptide
Sponsored by
Sunnybrook Health Sciences Centre
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for COVID-19 focused on measuring Artesunate, Infliximab, Imatinib, Dexamethasone, SARS-CoV-2, LSALT Peptide

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

Each participant must meet all of the following inclusion criteria to participate in this study:

  1. ≥ 18 years of age
  2. Has laboratory-confirmed SARS-CoV-2 infection as determined by PCR, or other commercial or public health assay in any specimen, within 14 days prior to randomization.
  3. Hospitalized at a participating centre
  4. Primary reason for hospitalization or subsequent in-hospital illness is because of acute COVID19 infection
  5. First admission for acute COVID19

In addition, there will be the below intervention-specific inclusion:

Randomization WHO will have no other specific inclusion criteria.

Randomization LSALT will have no other specific inclusion criteria.

Randomization Dex will have the following specific inclusion criteria

  1. On 10 days of steroid course and
  2. Receiving any supplemental oxygen for 10 days

Exclusion Criteria:

All participants meeting any of the following exclusion criteria at baseline will be excluded from participation in this study:

  1. Anticipated transfer to another hospital, within 72 hours, which is not a study site
  2. Expected to not survive beyond 24 hours
  3. Receiving one of the study drugs at time of enrolment

In addition, there will be the below intervention-specific exclusions:

Randomization WHO:

These will be drug-specific exclusions; patients will still be eligible for randomization in Randomization WHO to the other available study drugs (in randomization WHO or subsequent randomizations).

Artesunate:

1. Known hypersensitivity to artesunate

Imatinib:

  1. Pregnant or breastfeeding;
  2. Known hypersensitivity to imatinib;
  3. Liver transaminases (either ALT or AST) > 5x upper limit of normal

Infliximab:

  1. Known moderate or severe heart failure, per treating clinician, defined as New York Heart Association (NYHA) class III or IV
  2. Known or suspected active tuberculosis
  3. Known hypersensitivity to infliximab

Randomization LSALT:

  1. Known hypersensitivity or prior use of LSALT peptide.
  2. Pregnant or breastfeeding

Randomization Dex:

1. Receiving glucocorticoids for a specific, non-COVID-19 indication

Sites / Locations

  • Peter Lougheed Centre
  • Foothills Medical Centre
  • Rockyview General Hospital
  • South Health Campus
  • Royal Alexandra Hospital
  • Misericordia Community Hospital
  • University of Alberta Hopsital
  • Grey Nuns Community Hospital
  • Interior Health Royal Inland Hospital
  • Lions Gate Hospital
  • Richmond Hospital
  • Vancouver General Hospital, Vancouver Coastal Health, Univeristy of British Columbia
  • St Paul's Hospital
  • Island Health - Royal Jubilee Hospital
  • Island Health - Victoria General Hospital
  • Island Health - Nanaimo Regional General Hospital
  • St. Boniface Hospital
  • Health Sciences Centre
  • Grace General Hospital
  • Eastern Regional Health Authority
  • Nova Scotia Health Authority
  • Royal Victoria Regional Health Centre
  • William Osler Health System - Brampton Civic Hospital
  • William Osler Health System - Etobicoke General Hospital
  • St. Joseph's Healthcare Hamilton
  • St.Joseph's Health Care
  • University Hospital
  • Victoria Hospital
  • Markham Stouffville Hospital
  • Trillium Health Partners -Mississauga Site
  • Trillium Health Partners-Credit Valley Hospital
  • The Ottawa Hospital - General Campus
  • Hôpital Montfort
  • The Ottawa Hospital - Civic Campus
  • Queensway Carleton Hospital
  • Niagara Health
  • Scarborough Health Network - Centenary Hospital
  • Scarborough Health Network - General Hospital
  • Scarborough Health Network - Birchmount Hospital
  • Thunder Bay Regional Health Sciences Centre
  • North York General Hospital
  • Humber River Hospital
  • Michael Garron Hospital
  • Sunnybrook Health Sciences Centre
  • St. Michael's Hospital
  • Mount Sinai Hospital
  • Toronto Western Hospital
  • Unity Health Toronto - St. Joseph's Health Centre
  • Centre Hospitalier de l'Université de Montréal (CHUM)
  • McGill University Health Centre-Glen Site Royal Victoria Hospital
  • CHU de Québec - Université Laval
  • Institut Universitaire de Cardiologie et de Pneumologie de Québec- Université Laval
  • Centre Intégré Universitaire de Santé et de Services Sociaux de l'Estrie - Centre Hospitalier Universitaire de Sherbrooke

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm 5

Arm 6

Arm Type

Experimental

Experimental

Experimental

Experimental

Experimental

No Intervention

Arm Label

Artesunate

Imatinib

Infliximab

Dexamethasone

LSALT Peptide

Control (Standard Care)

Arm Description

Subjects will be randomized Artesunate vs Imatinib vs Infliximab vs standard of care

Subjects will be randomized Artesunate vs Imatinib vs Infliximab vs standard of care

Subjects will be randomized Artesunate vs Imatinib vs Infliximab vs standard of care

Subjects will be randomized between Dexamethasone vs standard of care.

Subjects will be randomized between LSALT vs standard of care.

This arm will receive standard supportive care guidelines for COVID-19. It is expected to vary regionally and may change throughout the trial based on new and emerging data on best care guidelines for patients.

Outcomes

Primary Outcome Measures

Randomization WHO- Mortality
All-cause mortality, assessed at hospital discharge.
Randomization Dex- Clinical Status
Position on the WHO Ordinal scale at 28 days post-randomization. Ordinal Scale Table: 0 Uninfected; 1-3 Ambulatory; 4-5 Hospitalized/ Mild disease; 6-9 Hospitalized/ Severe Disease; 10 Death
Randomization LSALT- Respiratory support
Number of days respiratory support free days

Secondary Outcome Measures

Evaluation of the clinical effectiveness of study drugs
To be compared to the control arm on duration of hospitalization
Need for invasive mechanical ventilation
CU admission, hospital and ICU length of stay, days alive and free of vasopressors, ventilation, and renal replacement therapy (RRT
Mortality
Mortality after Randomization

Full Information

First Posted
March 23, 2020
Last Updated
October 12, 2023
Sponsor
Sunnybrook Health Sciences Centre
Collaborators
AbbVie, Apotex Inc., World Health Organization, University of British Columbia, Arch Biopartners Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT04330690
Brief Title
Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial
Acronym
CATCO
Official Title
A Multi-centre, Adaptive, Randomized, Open-label, Controlled Clinical Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Patients (CATCO: Canadian Treatments for COVID-19), in Conjunction With the Public Health Emergency SOLIDARITY Trial (World Health Organization)
Study Type
Interventional

2. Study Status

Record Verification Date
January 2023
Overall Recruitment Status
Active, not recruiting
Study Start Date
March 18, 2020 (Actual)
Primary Completion Date
March 10, 2024 (Anticipated)
Study Completion Date
May 18, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Sunnybrook Health Sciences Centre
Collaborators
AbbVie, Apotex Inc., World Health Organization, University of British Columbia, Arch Biopartners Inc.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This study is an adaptive, randomized, open-label, controlled clinical trial, in collaboration with countries around the world through the World Health Organization.
Detailed Description
Subjects will be randomized, across one, two, three or up to four separate randomizations, to receive either standard-of-care products or the study medication plus standard of care, while being hospitalized for COVID-19. Randomization WHO: Imatinib vs Infliximab vs Artesunate vs Standard of care Randomization Dex: Dexamethasone vs Standard of care Randomization LSALT: LSALT Peptide vs Standard of care Hospitalized subjects will require blood sampling for screening and on days 1 and 5.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
COVID-19
Keywords
Artesunate, Infliximab, Imatinib, Dexamethasone, SARS-CoV-2, LSALT Peptide

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Masking Description
Endpoint assessment
Allocation
Randomized
Enrollment
2900 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Artesunate
Arm Type
Experimental
Arm Description
Subjects will be randomized Artesunate vs Imatinib vs Infliximab vs standard of care
Arm Title
Imatinib
Arm Type
Experimental
Arm Description
Subjects will be randomized Artesunate vs Imatinib vs Infliximab vs standard of care
Arm Title
Infliximab
Arm Type
Experimental
Arm Description
Subjects will be randomized Artesunate vs Imatinib vs Infliximab vs standard of care
Arm Title
Dexamethasone
Arm Type
Experimental
Arm Description
Subjects will be randomized between Dexamethasone vs standard of care.
Arm Title
LSALT Peptide
Arm Type
Experimental
Arm Description
Subjects will be randomized between LSALT vs standard of care.
Arm Title
Control (Standard Care)
Arm Type
No Intervention
Arm Description
This arm will receive standard supportive care guidelines for COVID-19. It is expected to vary regionally and may change throughout the trial based on new and emerging data on best care guidelines for patients.
Intervention Type
Drug
Intervention Name(s)
Artesunate
Intervention Description
2.4 mg/kg at 0 hours, 12 hours, 24 hours, and then daily for a total of 7 days plus standard of care
Intervention Type
Drug
Intervention Name(s)
Imatinib
Intervention Description
400 mg enterally daily for 14 days plus standard of care
Intervention Type
Drug
Intervention Name(s)
Infliximab
Intervention Description
5 mg/kg IV given one time, over 2 hours plus standard of care
Intervention Type
Drug
Intervention Name(s)
Dexamethasone
Intervention Description
6 mg IV/oral for a further five days, followed by a five day taper of 4 mg x 2 days and 2 mg x 3 days, for a total 20 day steroid course. If randomized to standard of care, discontinue the corticosteroid on day 10
Intervention Type
Drug
Intervention Name(s)
LSALT Peptide
Intervention Description
5 mg , 2 hour IV infusion once daily for up to 14 consecutive days
Primary Outcome Measure Information:
Title
Randomization WHO- Mortality
Description
All-cause mortality, assessed at hospital discharge.
Time Frame
28 days
Title
Randomization Dex- Clinical Status
Description
Position on the WHO Ordinal scale at 28 days post-randomization. Ordinal Scale Table: 0 Uninfected; 1-3 Ambulatory; 4-5 Hospitalized/ Mild disease; 6-9 Hospitalized/ Severe Disease; 10 Death
Time Frame
28 days
Title
Randomization LSALT- Respiratory support
Description
Number of days respiratory support free days
Time Frame
28 days
Secondary Outcome Measure Information:
Title
Evaluation of the clinical effectiveness of study drugs
Description
To be compared to the control arm on duration of hospitalization
Time Frame
24 months
Title
Need for invasive mechanical ventilation
Time Frame
24 months
Title
CU admission, hospital and ICU length of stay, days alive and free of vasopressors, ventilation, and renal replacement therapy (RRT
Time Frame
24 months
Title
Mortality
Description
Mortality after Randomization
Time Frame
12 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Each participant must meet all of the following inclusion criteria to participate in this study: ≥ 18 years of age Has laboratory-confirmed SARS-CoV-2 infection as determined by PCR, or other commercial or public health assay in any specimen, within 14 days prior to randomization. Hospitalized at a participating centre Primary reason for hospitalization or subsequent in-hospital illness is because of acute COVID19 infection First admission for acute COVID19 In addition, there will be the below intervention-specific inclusion: Randomization WHO will have no other specific inclusion criteria. Randomization LSALT will have no other specific inclusion criteria. Randomization Dex will have the following specific inclusion criteria On 10 days of steroid course and Receiving any supplemental oxygen for 10 days Exclusion Criteria: All participants meeting any of the following exclusion criteria at baseline will be excluded from participation in this study: Anticipated transfer to another hospital, within 72 hours, which is not a study site Expected to not survive beyond 24 hours Receiving one of the study drugs at time of enrolment In addition, there will be the below intervention-specific exclusions: Randomization WHO: These will be drug-specific exclusions; patients will still be eligible for randomization in Randomization WHO to the other available study drugs (in randomization WHO or subsequent randomizations). Artesunate: 1. Known hypersensitivity to artesunate Imatinib: Pregnant or breastfeeding; Known hypersensitivity to imatinib; Liver transaminases (either ALT or AST) > 5x upper limit of normal Infliximab: Known moderate or severe heart failure, per treating clinician, defined as New York Heart Association (NYHA) class III or IV Known or suspected active tuberculosis Known hypersensitivity to infliximab Randomization LSALT: Known hypersensitivity or prior use of LSALT peptide. Pregnant or breastfeeding Randomization Dex: 1. Receiving glucocorticoids for a specific, non-COVID-19 indication
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Srinivas Murthy, MD
Organizational Affiliation
Provincial Health Services Authority
Official's Role
Principal Investigator
Facility Information:
Facility Name
Peter Lougheed Centre
City
Calgary
State/Province
Alberta
ZIP/Postal Code
T1Y 6J4
Country
Canada
Facility Name
Foothills Medical Centre
City
Calgary
State/Province
Alberta
ZIP/Postal Code
T2N 2T9
Country
Canada
Facility Name
Rockyview General Hospital
City
Calgary
State/Province
Alberta
ZIP/Postal Code
T2V 1P9
Country
Canada
Facility Name
South Health Campus
City
Calgary
State/Province
Alberta
ZIP/Postal Code
T3M 1M4
Country
Canada
Facility Name
Royal Alexandra Hospital
City
Edmonton
State/Province
Alberta
ZIP/Postal Code
T5K0L4
Country
Canada
Facility Name
Misericordia Community Hospital
City
Edmonton
State/Province
Alberta
ZIP/Postal Code
T5R 4H5
Country
Canada
Facility Name
University of Alberta Hopsital
City
Edmonton
State/Province
Alberta
ZIP/Postal Code
T6G 2B7
Country
Canada
Facility Name
Grey Nuns Community Hospital
City
Edmonton
State/Province
Alberta
ZIP/Postal Code
T6L 5X8
Country
Canada
Facility Name
Interior Health Royal Inland Hospital
City
Kamloops
State/Province
British Columbia
ZIP/Postal Code
V2C2T1
Country
Canada
Facility Name
Lions Gate Hospital
City
North Vancouver
State/Province
British Columbia
ZIP/Postal Code
V7L 2L7
Country
Canada
Facility Name
Richmond Hospital
City
Richmond
State/Province
British Columbia
ZIP/Postal Code
V6X 1A2
Country
Canada
Facility Name
Vancouver General Hospital, Vancouver Coastal Health, Univeristy of British Columbia
City
Vancouver
State/Province
British Columbia
ZIP/Postal Code
V5Z1M9
Country
Canada
Facility Name
St Paul's Hospital
City
Vancouver
State/Province
British Columbia
ZIP/Postal Code
V6Z 1Y6
Country
Canada
Facility Name
Island Health - Royal Jubilee Hospital
City
Victoria
State/Province
British Columbia
ZIP/Postal Code
V8R 1J8
Country
Canada
Facility Name
Island Health - Victoria General Hospital
City
Victoria
State/Province
British Columbia
ZIP/Postal Code
V8Z 6R5
Country
Canada
Facility Name
Island Health - Nanaimo Regional General Hospital
City
Victoria
State/Province
British Columbia
ZIP/Postal Code
V9S 2B7
Country
Canada
Facility Name
St. Boniface Hospital
City
Winnipeg
State/Province
Manitoba
ZIP/Postal Code
R2H 2A6
Country
Canada
Facility Name
Health Sciences Centre
City
Winnipeg
State/Province
Manitoba
ZIP/Postal Code
R3A 1R9
Country
Canada
Facility Name
Grace General Hospital
City
Winnipeg
State/Province
Manitoba
ZIP/Postal Code
R3J 3M7
Country
Canada
Facility Name
Eastern Regional Health Authority
City
Saint John's
State/Province
Newfoundland and Labrador
ZIP/Postal Code
A1B 3V6
Country
Canada
Facility Name
Nova Scotia Health Authority
City
Halifax
State/Province
Nova Scotia
ZIP/Postal Code
B3S 0H6
Country
Canada
Facility Name
Royal Victoria Regional Health Centre
City
Barrie
State/Province
Ontario
ZIP/Postal Code
L4M 6M2
Country
Canada
Facility Name
William Osler Health System - Brampton Civic Hospital
City
Brampton
State/Province
Ontario
ZIP/Postal Code
L6R 3J7
Country
Canada
Facility Name
William Osler Health System - Etobicoke General Hospital
City
Etobicoke
State/Province
Ontario
ZIP/Postal Code
M9V 1R8
Country
Canada
Facility Name
St. Joseph's Healthcare Hamilton
City
Hamilton
State/Province
Ontario
ZIP/Postal Code
L8N 4A6
Country
Canada
Facility Name
St.Joseph's Health Care
City
London
State/Province
Ontario
ZIP/Postal Code
N6A 4V2
Country
Canada
Facility Name
University Hospital
City
London
State/Province
Ontario
ZIP/Postal Code
N6A 5A5
Country
Canada
Facility Name
Victoria Hospital
City
London
State/Province
Ontario
ZIP/Postal Code
N6A 5W9
Country
Canada
Facility Name
Markham Stouffville Hospital
City
Markham
State/Province
Ontario
ZIP/Postal Code
L3P 7P3
Country
Canada
Facility Name
Trillium Health Partners -Mississauga Site
City
Mississauga
State/Province
Ontario
ZIP/Postal Code
L5B 1B8
Country
Canada
Facility Name
Trillium Health Partners-Credit Valley Hospital
City
Mississauga
State/Province
Ontario
ZIP/Postal Code
L5M 2N1
Country
Canada
Facility Name
The Ottawa Hospital - General Campus
City
Ottawa
State/Province
Ontario
ZIP/Postal Code
K1H 8L6
Country
Canada
Facility Name
Hôpital Montfort
City
Ottawa
State/Province
Ontario
ZIP/Postal Code
K1K 0T2
Country
Canada
Facility Name
The Ottawa Hospital - Civic Campus
City
Ottawa
State/Province
Ontario
ZIP/Postal Code
K1Y 4E9
Country
Canada
Facility Name
Queensway Carleton Hospital
City
Ottawa
State/Province
Ontario
ZIP/Postal Code
K2H 8P4
Country
Canada
Facility Name
Niagara Health
City
Saint Catharines
State/Province
Ontario
ZIP/Postal Code
L2S 0A9
Country
Canada
Facility Name
Scarborough Health Network - Centenary Hospital
City
Scarborough
State/Province
Ontario
ZIP/Postal Code
M1E4B9
Country
Canada
Facility Name
Scarborough Health Network - General Hospital
City
Scarborough
State/Province
Ontario
ZIP/Postal Code
M1P2V5
Country
Canada
Facility Name
Scarborough Health Network - Birchmount Hospital
City
Scarborough
State/Province
Ontario
ZIP/Postal Code
M1W3W3
Country
Canada
Facility Name
Thunder Bay Regional Health Sciences Centre
City
Thunder Bay
State/Province
Ontario
ZIP/Postal Code
P7B 6V4
Country
Canada
Facility Name
North York General Hospital
City
Toronto
State/Province
Ontario
ZIP/Postal Code
M2K 1E1
Country
Canada
Facility Name
Humber River Hospital
City
Toronto
State/Province
Ontario
ZIP/Postal Code
M3M 0B2
Country
Canada
Facility Name
Michael Garron Hospital
City
Toronto
State/Province
Ontario
ZIP/Postal Code
M4C 3E7
Country
Canada
Facility Name
Sunnybrook Health Sciences Centre
City
Toronto
State/Province
Ontario
ZIP/Postal Code
M4N3M5
Country
Canada
Facility Name
St. Michael's Hospital
City
Toronto
State/Province
Ontario
ZIP/Postal Code
M5B 1W8
Country
Canada
Facility Name
Mount Sinai Hospital
City
Toronto
State/Province
Ontario
ZIP/Postal Code
M5G 1X5
Country
Canada
Facility Name
Toronto Western Hospital
City
Toronto
State/Province
Ontario
ZIP/Postal Code
M5T2S8
Country
Canada
Facility Name
Unity Health Toronto - St. Joseph's Health Centre
City
Toronto
State/Province
Ontario
ZIP/Postal Code
M6R1B5
Country
Canada
Facility Name
Centre Hospitalier de l'Université de Montréal (CHUM)
City
Montréal
State/Province
Quebec
ZIP/Postal Code
H2X 0A9
Country
Canada
Facility Name
McGill University Health Centre-Glen Site Royal Victoria Hospital
City
Montréal
State/Province
Quebec
ZIP/Postal Code
H4A 3J1
Country
Canada
Facility Name
CHU de Québec - Université Laval
City
Québec
State/Province
Quebec
ZIP/Postal Code
G1J 1Z4
Country
Canada
Facility Name
Institut Universitaire de Cardiologie et de Pneumologie de Québec- Université Laval
City
Québec
State/Province
Quebec
ZIP/Postal Code
G1V 4G5
Country
Canada
Facility Name
Centre Intégré Universitaire de Santé et de Services Sociaux de l'Estrie - Centre Hospitalier Universitaire de Sherbrooke
City
Sherbrooke
State/Province
Quebec
ZIP/Postal Code
J1H 5N4
Country
Canada

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
As per World Health Organization policies on data sharing in a Public Health Emergency, any clinical trial outcome data will be shared at the earliest possible opportunity. In addition, given the nature of this protocol, being performed across regions, the DSMB may access other regions trials, and possibly recommend alterations in study design based on accumulating data, through a centralized data repository being built under the auspices of the World Health Organization. Data Sharing for Secondary Research Data from this study may be used for secondary research. All of the individual subject data collected during the trial will be made available after de-identification through expert determination. The SAP and Analytic Code will also be made available. This data will be available immediately following publication, with no end date, as part of data sharing requirements from journals and funding agencies.
IPD Sharing Time Frame
Unknown and variable
Citations:
PubMed Identifier
35045989
Citation
Ali K, Azher T, Baqi M, Binnie A, Borgia S, Carrier FM, Cavayas YA, Chagnon N, Cheng MP, Conly J, Costiniuk C, Daley P, Daneman N, Douglas J, Downey C, Duan E, Duceppe E, Durand M, English S, Farjou G, Fera E, Fontela P, Fowler R, Fralick M, Geagea A, Grant J, Harrison LB, Havey T, Hoang H, Kelly LE, Keynan Y, Khwaja K, Klein G, Klein M, Kolan C, Kronfli N, Lamontagne F, Lau R, Fralick M, Lee TC, Lee N, Lim R, Longo S, Lostun A, MacIntyre E, Malhame I, Mangof K, McGuinty M, Mergler S, Munan MP, Murthy S, O'Neil C, Ovakim D, Papenburg J, Parhar K, Parvathy SN, Patel C, Perez-Patrigeon S, Pinto R, Rajakumaran S, Rishu A, Roba-Oshin M, Rushton M, Saleem M, Salvadori M, Scherr K, Schwartz K, Semret M, Silverman M, Singh A, Sligl W, Smith S, Somayaji R, Tan DHS, Tobin S, Todd M, Tran TV, Tremblay A, Tsang J, Turgeon A, Vakil E, Weatherald J, Yansouni C, Zarychanski R; Canadian Treatments for COVID-19 (CATCO); Association of Medical Microbiology and Infectious Disease Canada (AMMI) Clinical Research Network and the Canadian Critical Care Trials Group. Remdesivir for the treatment of patients in hospital with COVID-19 in Canada: a randomized controlled trial. CMAJ. 2022 Feb 22;194(7):E242-E251. doi: 10.1503/cmaj.211698. Epub 2022 Jan 19.
Results Reference
result
PubMed Identifier
33264556
Citation
WHO Solidarity Trial Consortium; Pan H, Peto R, Henao-Restrepo AM, Preziosi MP, Sathiyamoorthy V, Abdool Karim Q, Alejandria MM, Hernandez Garcia C, Kieny MP, Malekzadeh R, Murthy S, Reddy KS, Roses Periago M, Abi Hanna P, Ader F, Al-Bader AM, Alhasawi A, Allum E, Alotaibi A, Alvarez-Moreno CA, Appadoo S, Asiri A, Aukrust P, Barratt-Due A, Bellani S, Branca M, Cappel-Porter HBC, Cerrato N, Chow TS, Como N, Eustace J, Garcia PJ, Godbole S, Gotuzzo E, Griskevicius L, Hamra R, Hassan M, Hassany M, Hutton D, Irmansyah I, Jancoriene L, Kirwan J, Kumar S, Lennon P, Lopardo G, Lydon P, Magrini N, Maguire T, Manevska S, Manuel O, McGinty S, Medina MT, Mesa Rubio ML, Miranda-Montoya MC, Nel J, Nunes EP, Perola M, Portoles A, Rasmin MR, Raza A, Rees H, Reges PPS, Rogers CA, Salami K, Salvadori MI, Sinani N, Sterne JAC, Stevanovikj M, Tacconelli E, Tikkinen KAO, Trelle S, Zaid H, Rottingen JA, Swaminathan S. Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results. N Engl J Med. 2021 Feb 11;384(6):497-511. doi: 10.1056/NEJMoa2023184. Epub 2020 Dec 2.
Results Reference
result
PubMed Identifier
36036936
Citation
Cheng M, Fowler R, Murthy S, Pinto R, Sheehan NL, Tseng A. Remdesivir in Patients With Severe Kidney Dysfunction: A Secondary Analysis of the CATCO Randomized Trial. JAMA Netw Open. 2022 Aug 1;5(8):e2229236. doi: 10.1001/jamanetworkopen.2022.29236.
Results Reference
result
PubMed Identifier
36199248
Citation
Lau VI, Fowler R, Pinto R, Tremblay A, Borgia S, Carrier FM, Cheng MP, Conly J, Costiniuk CT, Daley P, Duan E, Durand M, Fontela PS, Farjou G, Fralick M, Geagea A, Grant J, Keynan Y, Khwaja K, Lee N, Lee TC, Lim R, O'Neil CR, Papenburg J, Semret M, Silverman M, Sligl W, Somayaji R, Tan DHS, Tsang JLY, Weatherald J, Yansouni CP, Zarychanski R, Murthy S; E-CATCO authors, AMMI Clinical Research Network and Canadian Critical Care Trials Group. Cost-effectiveness of remdesivir plus usual care versus usual care alone for hospitalized patients with COVID-19: an economic evaluation as part of the Canadian Treatments for COVID-19 (CATCO) randomized clinical trial. CMAJ Open. 2022 Sep 6;10(3):E807-E817. doi: 10.9778/cmajo.20220077. Print 2022 Jul-Sep.
Results Reference
derived
PubMed Identifier
35609913
Citation
Essai CATCO (Canadian Treatments for COVID-19); pour le Reseau de recherche clinique de l'Association pour la microbiologie medicale et l'infectiologie Canada (AMMI Canada) le Groupe canadien de recherche en soins intensifs (CCCTG). Remdesivir chez les patients hospitalises pour la COVID-19 au Canada: essai clinique randomise et controle. CMAJ. 2022 May 24;194(20):E713-E723. doi: 10.1503/cmaj.211698-f. French.
Results Reference
derived
PubMed Identifier
34350582
Citation
Ansems K, Grundeis F, Dahms K, Mikolajewska A, Thieme V, Piechotta V, Metzendorf MI, Stegemann M, Benstoem C, Fichtner F. Remdesivir for the treatment of COVID-19. Cochrane Database Syst Rev. 2021 Aug 5;8(8):CD014962. doi: 10.1002/14651858.CD014962.
Results Reference
derived
Links:
URL
https://www.cmaj.ca/content/194/7/E242
Description
Remdesivir for the treatment of patients in hospital with COVID-19 in Canada: a randomized controlled trial
URL
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7727327/
Description
Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results
URL
https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2795734
Description
Remdesivir in Patients With Severe Kidney Dysfunction. A Secondary Analysis of the CATCO Randomized Trial

Learn more about this trial

Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial

We'll reach out to this number within 24 hrs